Immunocore HoldingsIMCR -1.72%76 Days Inventory is 1,576.38 as of Mar. 2026, which is 186% above its 10-year median of 550.98. GuruFocus rates IMCR with a GF Score™ of 76/100 and a GF Value™ of $46.16 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 635 Biotechnology companies, Immunocore Holdings ranks worse than 82.05% on this metric.
The historical rank and industry rank for Immunocore Holdings's Days Inventory or its related term are showing as below:
IMCR'
s Days Inventory Range Over the Past 10 Years
Min: 231.94 Med: 550.98 Max: 913.91
Current: 512.25
During the past 8 years, Immunocore Holdings's highest Days Inventory was 913.91. The lowest was 231.94. And the median was 550.98.
IMCR's Days Inventory is ranked worse than 82.05% of 635
companies
in the Biotechnology industry
Industry Median: 183.23
vs IMCR: 512.25
Immunocore Holdings's Days Inventory
increased
from Mar. 2025 (672.57) to Mar. 2026 (1,576.38).
It might indicate that Immunocore Holdings's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Immunocore Holdings's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.06.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Immunocore Holdings's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.07.
Immunocore Holdings (NAS:IMCR) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Immunocore Holdings's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Immunocore Holdings's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Immunocore Holdings Days Inventory Related Terms
Immunocore Holdings Days Inventory Historical Data
* Premium members only.
The historical data trend for Immunocore Holdings's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IMCR vs MAZE, DMRA, AVBP: Days Inventory Comparison
For the Biotechnology subindustry, Immunocore Holdings's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunocore Holdings Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immunocore Holdings's Days Inventory distribution charts can be found below:
* The bar in red indicates where Immunocore Holdings's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunocore Holdings (IMCR) has a Days Inventory of 1,576.38 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Immunocore Holdings and its competitors. This is 186% above median its historical median of 550.98. Over the past decade, Immunocore Holdings' Days Inventory has ranged from 231.94 to 913.91. According to the industry distribution chart, Immunocore Holdings ranks #521 out of 635 companies in the Biotechnology industry, placing it in the top 82%.
Is Immunocore Holdings' Days Inventory too high?
Immunocore Holdings' current Days Inventory of 1,576.38 is 186% above median its 10-year median of 550.98. Over the past 10 years, this metric has ranged from a low of 231.94 to a high of 913.91. The Biotechnology industry median Days Inventory is 183.23. Immunocore Holdings' value of 1,576.38 is 760.3% above this industry median. Based on the distribution chart, Immunocore Holdings ranks #521 out of 635 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Immunocore Holdings has a GF Score™ of 76/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Immunocore Holdings' Days Inventory compare to MAZE and DMRA?
According to the Biotechnology industry distribution chart, Immunocore Holdings ranks #521 out of 635 companies for Days Inventory. This places Immunocore Holdings in the lower half of its industry. The industry median Days Inventory is 183.23. Immunocore Holdings' value of 1,576.38 is 760.3% above this benchmark. Historically, Immunocore Holdings' own Days Inventory has ranged from 231.94 to 913.91 over the past decade. While the company's 10-year median is 550.98 vs. the industry median of 183.23, Immunocore Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.23, based on 635 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immunocore Holdings's current Days Inventory of 1,576.38 is 760.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Immunocore Holdings and its competitors. For the Biotechnology industry, the median Days Inventory is 183.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immunocore Holdings's current Days Inventory is 1,576.38, which is 186% above median its own 10-year median of 550.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunocore Holdings stock overvalued right now?
Based on GuruFocus' analysis, Immunocore Holdings (IMCR) is currently considered Possible Value Trap. The stock's GF Value™ is $46.16, compared to a current price of $31.94 — trading 30.8% below its estimated fair value. The current Days Inventory is 1,576.38, which is 186% above median its 10-year median of 550.98 and 760.3% above the Biotechnology industry median of 183.23. Immunocore Holdings' overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Immunocore Holdings (IMCR), the current Days Inventory is 1,576.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immunocore Holdings (IMCR) Overvalued in 2026?
Based on GuruFocus' analysis, Immunocore Holdings stock appears to be undervalued.
The current stock price of $31.94 is trading 30.8% below its estimated GF Value™ of $46.16.
GuruFocus considers Immunocore Holdings to be Possible Value Trap.
Key valuation signals for IMCR:
Days Inventory: 1,576.38 (186% above median its 10-year median of 550.98)
GF Value™: $46.16 vs. price of $31.94 (30.8% below fair value)
Industry Position: 760.3% above the Biotechnology median (#521 of 635)
No single metric tells the full story. See the IMCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
76GF Score
Get the complete analysis for IMCR
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMCR has been successfully added to your 
